Get started
CRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AG

CRISPR THERAPEUTICS AG

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CRSP/N trade ideas

CRSP - Bull PennantCRSP was on a roll since it broke out of consolidation range (>112) on Nov 27. It started to form a bull pennant for the past week giving late comers an opportunity to stake. There are 2 possible entries we can consider. The traditional way is to enter upon the break up of the bull pennant (this way the trade will almost always go our way). However, I do not mind entering at the lower end of the pennant (could mean longer wait before we see a good move). Either way, I would still place a stop loss abt $1 below the pennant low of 138. Trail it upwards once we have a reasonable profit. We do not know how high it can go eventually hence trail your stops upward (giving enough room to swing) or take partial profits along the way up.
NASDAQ:CRSPLong
by Juliac
Stock to watch: Crispr Therapeutics AG (CRSP) - re-uploadNASDAQ:CRSP Re-uploading the original idea from Nov 24 (which was brutally deleted by the moderators LOL) 👇🏻 Original chart from Nov 24 May be an interesting stock to trade: Buy/Sell Zones indicates a 20-day uptrend. Long-term target is 1 Fibonacci, short-term targets may be lower Fibonacci values. The pre-market shows a small potential recoil that can give a good Long entry point. Disclaimer: This article should not be considered as financial or investment advice. Trading digital assets involve risk and may resolve in the loss of your capital. Always be sure to understand the amount of risk involved and do your research before taking any trading/investment steps.
NASDAQ:CRSPLong
by randomname11
3
Re-visit my earlier call about CRSP/NTLA/EDITTo my followers; I made a call about these 3 companies couple of months back. Since then they have some good runs and the momentum seems to be getting even stronger. Check out this interview with Ms. Cathie Wood, founder and CEO of Ark Invest, about their technologies. www.youtube.com Personally I am holding some positions in these companies and looking for keep adding to it when time is right. Disclaimer, this is only for entertainment and education purposes and doesn't serve by any means as a buy or sell recommendation. Personally I hold both long term long positions and occasionally short term short position, for disclosure purpose.
NASDAQ:CRSP
by hanzhao311
1
Cup and Handle Patterns above PatternsAnother cup and handle has formed above the old cup and handle If you enjoy volatility this is a good one for you. This one may pull back again close to handle low of new cup and handle Remains to be seen Be patient and pick a good entry that works for you Stop to your tolerance or below handle low The last time this one reached long entry, iit did not hold on to the high. Deep pull back ensued and now CRSP seems to have energy again I see now a new all time high was just made but has pulled back again. If you like this stock, beware of volatility It appears Gene editing companies are hot as of late/TXG is another NV is high and short interest is mediocre but a bit higher than I like Be safe and be patient (o: Not a recommendation CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
NASDAQ:CRSPLong
by lauralea